UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): January 4, 2010
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-50298
|
98-0376008
|
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
|
of
incorporation)
|
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
7.01 REGULATION FD
DISCLOSURE
On
December 31, 2009, Oramed Pharmaceuticals Inc. issued a letter to its
shareholders reviewing its achievements in 2009 and discussing the significant
milestones for the beginning of 2010.
A copy of
the letter is attached to this Current Report on Form 8-K as Exhibit 99.1 and is
incorporated by reference herein.
ITEM
7.01 FINANCIAL STATEMENTS AND
EXHIBITS.
(d) Exhibits
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Letter
to shareholders dated December 31,
2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ORAMED PHARMACEUTICALS
INC.
|
||
|
Dated:
January 4, 2009
|
||
|
By:
|
/s/ Nadav
Kidron
|
|
|
Nadav
Kidron
|
||
|
President,
CEO and Director
|
||
Exhibit
Index
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Letter
to shareholders dated December 31,
2009.
|
Dear
Shareholder:
As
we are about to begin 2010, I would like to take the opportunity to look back on
the past year and note the progress that Oramed has made, and look at what is
expected in the near future. Last year, beyond the actual clinical trials,
Oramed was chosen to present at a number of significant scientific conferences,
widening our exposure to the greater scientific community. Also,
Oramed received a substantial grant from the Israeli Office of the Chief
Scientist. In August 2009, Frost & Sullivan awarded Oramed with the
2009 European Oral Drug Delivery Technology Innovation Award. All in all
this has been a very productive and exciting year for Oramed and we are hoping
to move Oramed to the next level in 2010.
At the
beginning of 2010, Oramed has significant milestones; which, if met
successfully, will lead Oramed to new heights and take us a step closer to
changing the paradigm for the treatment of Diabetes:
· Results of Phase 2b clinical trials
of Oramed's oral insulin capsule, being conducted in South
Africa are expected
at the end of the first quarter of 2010. These trials mark one of
the most important milestones to date for the drug, testing ORMD-0801 for the
first time on a large group of volunteers for an extended duration.
· Results are expected during the first
quarter of 2010 from the first-in-human clinical study of ORMD-0901, an oral
GLP1-analog.
· IND
submission for FDA approved Phase 2 clinical trials is expected in mid
2010.
On the
public side, after keeping a relatively low profile, Oramed has recently engaged
a new investor relations firm, Emerging Markets Consulting LLC (www.emergingmarketsllc.com
/www.themicrocapreport.com)
in order to enlarge the current investors cadre and expose Oramed to more
investors. EMC will start providing its services to Oramed in early January
2010. Oramed is also considering hiring a new public relations firm
to help expose the Oramed story to a broader audience.
On behalf
of the entire Oramed team I wish you all a happy and successful
year.
Best
Regards,
Nadav
Kidron,
Chief
Executive Officer